Evaluation of Riluzol effect as adjunctive therapy in patients with standard treatment-resistant obsessive-compulsive disorder

1- Determining the mean score of Y-BOCS in 2 groups of control and drug 2- Determining the average score in 12 weeks after starting the study Comparison of Y-BOCS change in week 0 and 12 between control and drug groups 4- The amount of side effects recorded between the two control and drug groups in week 12

Clinical trial with control group, with parallel groups, double-blind, randomized, phase 2 on 22 patients. Excel software rand function was used for randomization. Patients are randomly divided into two groups of drugs and placebo. We prepare the medicine and placebo with the same appearance (including color, size and design) and in the same package with a dose of 50 mg and provide it to the patients.

By referring the qualified patients to the office of Dr. Sayyah Bargard, a Psychiatrist, after examining the patient's condition, the drugs were randomly selected and delivered to the patient. All patients were followed up for 12 weeks.

1. People who are recognized as having obsessive-compulsive disorder by the DSM-V standard 2. Has no other mental disorder. 3. Has not been diagnosed with any respiratory disorders. 4. Do not consume alcohol and do not use drugs or stimulants. 5. Be between 18 and 65 years old. 6. The person in question should be treated with SSRI drug for at least 3 months with the maximum dose and has a score of 20 or higher in the Y-BOCS criterion.

Both groups of patients were told to take one pill every night for 12 weeks, and to report the symptoms of taking the pill by phone or in the attending physician's office. Medication or discontinuation is done.

Finding a low-complication and effective drug as adjunctive therapy in refractory obsessive-compulsive disorder.

Block randomization with 5 blocks will be performed for randomization of the study. The drug and placebo, which are made in exactly the same way, will be placed by the pharmacist unrelated to the research in equal packages of dark medicine with equal number, on the envelope with a label containing the information of the research center, how to use the medicine, patient number, and letters A or B will be placed for the drug group or placebo and the number will be registered in random order. The randomization tool will be statistical software that will be performed by the statistical analyzer of the study. When randomization is performed, each patient receives a code that will be recognized during the study. This code will be from 1 to 32 due to the small number of participants. The process of hiding and grouping patients and the type of medication they receive will not be disclosed to researchers.

Both the drug and the placebo are indistinguishable from the patients and the relevant medical staff because they are exactly the same size, shape and color. The psychiatrist, the researcher recording the patient's condition and the delivery of the drug, and the patient are not aware that the drug received is the main drug or placebo.